They dont try and up sale you
Eli Lilly said Thursday that its triple-agonist obesity drug retatrutide hit every primary and key secondary endpoint in TRIUMPH-1, the Phase 3 registration trial that will anchor the company's expected FDA filing
o , Application of GLP-1 and GLP-1MK-801 induced changes in fluorescence indicative of rises in intracellular calcium (%F/F 0 ) as shown by these representative fluorescent responses of two different Fura 2-AM loaded cells to application of GLP-1 (1 M) or GLP-1MK-801 (1 M)
Retatrutide is getting a lot of attention
Introduction With high and rising rates of adiposity and related morbidity, mortality, and healthcare expenditures, recently approved glucagon-like peptide 1 receptor agonists and related combination obesity medications (collectively referred to as GLP-1s1) are shifting the treatment landscape shifting the treatment landscape (we collectively refer to these as GLP-1s given this common practical usage by clinicians, policymakers, and the public
New GLP1-based multi-agonist therapies seem to be substantially more effective than older GLP1R agonists in reducing body weight but their safety requires ongoing scrutiny in trials assessing outcomes in individuals with obesity
